deltatrials
Completed PHASE2 NCT00004912

Megestrol and Exercise in Treating Patients With Cancer-Related Weight Loss

Phase II Trial of Progressive Resistance Training With Megestrol Acetate for the Treatment of Cancer-Related Weight Loss

Sponsor: National Cancer Institute (NCI)

Conditions Cachexia Fatigue Unspecified Adult Solid Tumor, Protocol Specific
Interventions megestrol acetate physical therapy
Updated 7 times since 2017 Last updated: May 17, 2012 Started: Jan 31, 2000 Primary completion: Nov 30, 2003 Completion: Nov 30, 2003

A PHASE2 clinical study on Cachexia and Fatigue, this trial is completed. The trial is conducted by National Cancer Institute (NCI) and has accumulated 7 data snapshots since 2000. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Apr 2022 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Apr 2022 [monthly]

    Completed PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Jan 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
  • Northwestern University
Data source: Northwestern University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Chicago, United States
  • • Evanston, United States
  • • Gainesville, United States
  • • Long Beach, United States
  • • North Little Rock, United States
  • • Raleigh, United States